# Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel

Study · id `cardio:ct-nct01643031` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01643031](<https://clinicaltrials.gov/study/NCT01643031>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01643031

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 500 participants.

## Technical summary

Registry record NCT01643031. Randomized; no masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2014-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 500 participants (planned count; ClinicalTrials.gov record NCT01643031, source copy `cardio:ctgov-nct01643031-2013-06-17`, retrieved 2026-10-26)
- Start date: 2012-08 (registry gives no type) (ClinicalTrials.gov record NCT01643031, source copy `cardio:ctgov-nct01643031-2013-06-17`, retrieved 2026-10-26)
- Primary completion: 2014-09 (anticipated) (ClinicalTrials.gov record NCT01643031, source copy `cardio:ctgov-nct01643031-2013-06-17`, retrieved 2026-10-26)
- Completion: 2014-10 (anticipated) (ClinicalTrials.gov record NCT01643031, source copy `cardio:ctgov-nct01643031-2013-06-17`, retrieved 2026-10-26)
- Countries: Israel (ClinicalTrials.gov record NCT01643031, source copy `cardio:ctgov-nct01643031-2013-06-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01643031-2013-06-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel
- Acronym: MATTIS-D
- Condition: Diabetes Mellitus
- Condition: Coronary Disease
- Intervention (Drug): Ticagrelor
- Intervention (Drug): Continued clopidogrel
- Lead sponsor: Rabin Medical Center
- Lead sponsor class: OTHER
- Collaborator: Tel Aviv Medical Center
- Collaborator class: OTHER
- Collaborator: Sheba Medical Center
- Collaborator class: OTHER\_GOV
- Collaborator: Meir Medical Center
- Collaborator class: OTHER
- Collaborator: Rambam Health Care Campus
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record: Ticagrelor (`cardio:ticagrelor`)
- Registry lists this organization as a collaborator: Sheba Medical Center (`cardio:org-sheba-medical-center`)
- Registry lists this organization as a collaborator: Meir Medical Center (`cardio:org-meir-medical-center`)
- Registry lists this organization as a collaborator: Rambam Health Care Campus (`cardio:org-rambam-health-care-campus`)

## Provenance

Content hash: 7c5bb03b4f27603c40117dfcc51f4ea9b6c88786fa6d9d5acf32dd54ebf3bdab
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
